Summary
Serum lipoproteins were determined in 15 patients before and during antihypertensive treatment with atenolol 0.1–0.2 g/day for a mean of 8 months. The mean blood pressure fell from 171/103 to 154/93 mm Hg (p<0.05). Significant lipoprotein changes were an increase in very low density triglycerides (VLDL-TG) from 1.21±0.95 (SD) to 1.62±1.24 mmol/l (p<0.01) and in low density (LDL) TG from 0.46±0.12 to 0.51±0.12 mmol/l (p<0.05). Together, these TG increases resulted in development of hypertriglyceridaemia in 7/15 patients during atenolol treatment. No effect on whole serum cholesterol or on the high density lipoprotein cholesterol concentrations were found. Thus, some patients on long term treatment with atenolol seem to receive the benefit of normotension at the cost of hypertriglyceridaemia. This may have practical implications, since hypertriglyceridaemia constitutes an important risk factor for atherosclerosis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Waal-Manning HJ, Simpson FO (1977) Beta-blockers and lipid metabolism. Br Med J 2: 705
Shaw J, England JDF, Hua ASP (1978) Beta-blockers and plasma triglycerides. Br Med J 1: 986
Day JL, Simpson N, Metcalfe J, Page RL (1979) Metabolic consequences of atenolol and propranolol in treatment of essential hypertension. Br Med J 1: 77–80
Tanaka N, Sakaguchi S, Oshige K, Niimura T, Kanehisa T (1976) Effect of chronic administration of propranolol on lipoprotein composition. Metabolism 25: 1071–1075
Carlson K (1973) Lipoprotein fractionation. J Clin Pathol 26: (Suppl 5) 32–37
Fletcher MJ (1978) A colorimetric method for estimating serum triglycerides. J Clin Chim Acta 22: 393–397
Zlatkis A, Zak B, Boyle J (1973) A new method for direct determination of serum cholesterol. J Lab Clin Med 41: 486–492
Carlson LA, Ericsson M (1975) Quantitative and qualitative serum lipoprotein analysis. Part I. Studies in healthy men and women. Atherosclerosis 21: 417–433
Rössner S (1978) Serum lipid changes during treatment with antihypertensive drugs. Acta Med. Scand 628 (Suppl): 89–92
Rosenman RH, Brand RJ, Jenkins CD, Friedman M, Strans R (1975) Coronary heart disease in the Western Collaborative Group Study. J Am Med Assoc 233: 872–877
Albrink MJ, Meigs JW, Man EB (1961) Serum lipids, hypertension and coronary artery disease. J Med 31: 4–8
Carlson LA, Böttiger LE (1972) Ischaemic heart disease in relation to fasting values of plasma triglycerides and cholesterol. Stockholm Prospective Study. Lancet 1: 865–868
Leren P, Foss PO, Helgeland A, Hjermann I, Holme I, Lund-Larsen PG (1980) Effects of propranolol and prazosin on blood lipids. Lancet 2: 4–6
England JDF, Simons LA, Gibson JC, Carlton M (1980) The effects of metoprolol and atenolol on plasma high density lipoprotein levels in man. Clin Exp Pharmacol Physiol 3: 329–333
Reinis Z, Lojda Z, Heyrovsky A, Horakova D, Reisenauer R (1976) Effect of beta-blocking agents in experimental atherosclerosis of cocks. Rev Czech. Med. 22: 117–126
Whittington-Coleman PJ, Carrier O Jr, Douglas BH (1973) The effects of propranolol on cholesterol-induced atheromatous lesions. Atherosclerosis 18: 337–345
Pick R, Glick G (1977) Effects of propranolol, minoxidil, and clofibrate on cholesterol-induced atherosclerosis in stumptail macaques (Macaca arctoides). Atherosclerosis 27: 71–77
Ames RP, Hill P (1976) Increase in serum-lipids during treatment of hypertension with chlorthalidone. Lancet 1: 721–723
Berglund G (1978) Fyra års uppföljning av blodtryckssänkning och metabola förändringar under Salures-K- och Inderalbehandling. Observ Med Ferrosan 5: 39–41
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Eliasson, K., Lins, L.E. & Rössner, S. Serum lipoprotein changes during atenolol treatment of essential hypertension. Eur J Clin Pharmacol 20, 335–338 (1981). https://doi.org/10.1007/BF00615401
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00615401